Additionally, we further examined the impact of TXNIP on patient survival in a BRAF-mutant advanced melanoma cohort using the TCGA database and found that patients with high TXNIP expression had a significantly longer median survival time than those with low expression (Log Rank, P = 0.047), indicating that high expression of TXNIP is a protective prognostic factor for BRAF-mutant advanced melanoma (Supplementary Fig. 5B). Here, BRAF is linked to melanoma.